Prokidney (PROK) Operating Margin (2024 - 2026)
Prokidney's (PROK) quarterly Operating Margin came in at 32248.67% in Q2 2026, down 1428079.0% year-over-year from N/an in Q2 2025, and down 62.2% quarter-over-quarter from 19881.86% in Q1 2026.
Powered by 
Analysis
Prokidney (PROK) Operating Margin (2024 - 2026) Analysis & Trends
Prokidney (PROK) has reported Operating Margin for 3 consecutive years, with 32248.67% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Margin fell 1428079.0% year-over-year to 32248.67% in Q2 2026; TTM through Jun 2026 was 21664.55%, a 1280244.0% increase from a year earlier, with the FY2025 full-year figure at 18477.83%, up 22320112.0% from the prior year.
- Operating Margin was 32248.67% for Q2 2026 at Prokidney, down from 19881.86% in the prior quarter.
- Over five years, Operating Margin peaked at 17759.91% in Q3 2025 and troughed at 67856.58% in Q4 2024.
- A 3-year average of 27696.37% and a median of 19881.86% in 2026 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin soared 4769169 bps in 2025 and plunged 1428079 bps in 2026, its largest moves.
- Over 3 years, Operating Margin stood at 67856.58% in 2024, then soared by 70 bps to 20164.89% in 2025, then slumped by 60 bps to 32248.67% in 2026.
- The last three Operating Margin figures came in at 32248.67% (Q2 2026), 19881.86% (Q1 2026), and 20164.89% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.82 Bn | 3.52 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.67 Bn | 2.71 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -25,827.14% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.98 Bn | 1.81 Bn | 56.40 Mn | 0.56% |
| 10 | Prokidney | 346.07 Mn | 346.07 Mn | - | -32,248.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32,248.67% |
| Mar 31, 2026 | -19,881.86% |
| Dec 31, 2025 | -20,164.89% |
| Sep 30, 2025 | -17,759.91% |
| Jun 30, 2025 | -17,967.87% |
| Mar 31, 2025 | -17,994.78% |
| Dec 31, 2024 | -67,856.58% |